Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: review of recent cases in psychiatry drugs.

Younis IR, Rogers H, Zhang H, Zhu H, Uppoor RS, Mehta MU.

J Clin Pharmacol. 2013 Oct;53(10):1005-9. doi: 10.1002/jcph.118. Epub 2013 Jul 10. Review.

PMID:
23842865
2.

An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia.

Younis IR, Laughren TP, Wang Y, Mathis M, Gobburu JV.

J Clin Psychopharmacol. 2013 Apr;33(2):152-6. doi: 10.1097/JCP.0b013e31828393a8.

PMID:
23422374
3.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review.

PMID:
21129135
5.

A proposal for scientific framework enabling specific population drug dosing recommendations.

Jadhav PR, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V, Stockbridge N, Powell JR.

J Clin Pharmacol. 2015 Oct;55(10):1073-8. doi: 10.1002/jcph.579. Epub 2015 Jul 30.

PMID:
26109076
6.

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

Potkin SG, Preskorn S, Hochfeld M, Meng X.

J Clin Psychopharmacol. 2013 Feb;33(1):3-10. doi: 10.1097/JCP.0b013e31827c0314.

PMID:
23277250
7.

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.

Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L.

Curr Med Res Opin. 2010 Feb;26(2):377-87. doi: 10.1185/03007990903482772. Review.

PMID:
20001492
8.

Quantitative clinical pharmacology is transforming drug regulation.

Peck CC.

J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):617-28. doi: 10.1007/s10928-010-9171-3. Epub 2010 Oct 27. Review.

PMID:
20978827
9.

Stimulants and neuroleptic withdrawal dyskinesia.

Connor DF.

J Am Acad Child Adolesc Psychiatry. 1998 Mar;37(3):247-8. No abstract available.

PMID:
9519625
10.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
11.

Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.

Ozdemir V, Williams-Jones B, Graham JE, Preskorn SH, Gripeos D, Glatt SJ, Friis RH, Reist C, Szabo S, Lohr JB, Someya T.

J Investig Med. 2007 Apr;55(3):130-41. doi: 10.2310/6650.2007.06042.

PMID:
17481382
12.

Pharmacogenomic potential of psychiatric medications and CYP2D6.

Foley KF, Quigley DI.

MLO Med Lab Obs. 2010 Jan;42(1):32-4.

PMID:
20180465
13.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
14.

How dosing of ziprasidone in a state hospital system differs from product labeling.

Citrome L, Jaffe A, Levine J.

J Clin Psychiatry. 2009 Jul;70(7):975-82.

PMID:
19653974
15.

Paliperidone: a new extended-release oral atypical antipsychotic.

Dlugosz H, Nasrallah HA.

Expert Opin Pharmacother. 2007 Oct;8(14):2307-13. Review.

PMID:
17927485
16.

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S.

Arch Gen Psychiatry. 2003 Feb;60(2):204-11.

PMID:
12578439
17.

Acute dyskinesia on starting methylphenidate after risperidone withdrawal.

Hollis CP, Thompson A.

Pediatr Neurol. 2007 Oct;37(4):287-8.

PMID:
17903675
18.

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.

Citrome L.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):873-88. doi: 10.1517/17425255.2012.693160. Epub 2012 May 25. Review.

PMID:
22632481
19.

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies.

RuaƱo G, Collins JM, Dorner AJ, Wang SJ, Guerciolini R, Huang SM.

Pharmacogenomics. 2004 Jul;5(5):513-7. No abstract available.

PMID:
15212588
20.

Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives.

Ibrahim S, Honig P, Huang SM, Gillespie W, Lesko LJ, Williams RL.

J Clin Pharmacol. 2000 Jan;40(1):31-8. Review.

PMID:
10631619

Supplemental Content

Support Center